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Abstract 
Background 
An iron-overloaded state has been reported to be associated with insulin resistance. On the other 
hand, conditions such as classical hemochromatosis (where iron overload occurs primarily in the 
liver) have been reported to be associated with increased insulin sensitivity. The reasons for 
these contradictory findings are unclear. In this context, the effects of increased intracellular iron 
per se on insulin signaling in hepatocytes are not known.  
Methods 
Mouse primary hepatocytes were loaded with iron in vitro by incubation with ferric ammonium 
citrate (FAC). Intracellular events related to insulin signaling, as well as changes in gene 
expression and hepatocyte glucose production (HGP), were studied in the presence and absence 
of insulin and/or forskolin (a glucagon mimetic). 
Results: 
In vitro iron-loading of hepatocytes resulted in phosphorylation-mediated activation of Akt and 
AMP-activated protein kinase. This was associated with decreased basal and forskolin-
stimulated HGP. Iron attenuated forskolin-mediated induction of the key gluconeogenic enzyme, 
glucose-6-phosphatase. It also attenuated activation of the Akt pathway in response to insulin, 
which was associated with decreased protein levels of insulin receptor substrates 1 and 2, 
constituting insulin resistance. 
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Conclusions 
Increased intracellular iron has dual effects on insulin sensitivity in hepatocytes. It increased 
basal activation of the Akt pathway, but decreased activation of this pathway in response to 
insulin. 
General significance 
These findings may help explain why both insulin resistance and increased sensitivity have been 
observed in iron-overloaded states. They are of relevance to a variety of disease conditions 
characterized by hepatic iron overload and increased risk of diabetes.  
Keywords: iron; insulin resistance; Akt; gluconeogenesis; diabetes mellitus; hemochromatosis 
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List of abbreviations: 
ACC (acetyl CoA carboxylase), Akt (acute transforming retrovirus thymoma), AMPK (5’-
adenosine monophosphate-activated protein kinase), AMPKK (AMPK kinase), BCA 
(bicinchoninic acid), DFO (desferrioxamine), FAC (ferric ammonium citrate), FoxO1 (forkhead 
box protein O1), Gsk3β (glycogen synthase kinase 3β), Hamp1 (hepcidin anti-microbial 
peptide), IR (insulin resistance), IRS (insulin receptor substrate), JNK (c-Jun N-terminal kinase), 
LKB1 (liver kinase B1), mTOR (mechanistic target of rapamycin), PFKFP 
(phosphofructokinase-2/fructose bisphophatase-2), PGC1α (peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha), PVDF (polyvinylidene fluoride), SPSS (Statistical Package 
for the Social Sciences), TfR1 (transferrin receptor 1). 
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1. Introduction 
Insulin resistance (IR) is the hallmark of type 2 diabetes mellitus (T2DM). Several lines of 
evidence suggest that iron plays a role in the pathogenesis of IR [1]. For example, children with 
thalassemia major, who are treated with repeated blood transfusions and have increased body 
iron stores, develop hyperinsulinemia and IR before they develop diabetes [2]. Aggressive iron 
chelation has reduced the incidence of diabetes in patients with thalassemia [3]. Further evidence 
for the role of iron in IR is provided by improvements in insulin sensitivity following 
phlebotomy, both in patients with T2DM [4] and in healthy individuals [5]. Iron-deficient rats 
show increased peripheral glucose uptake in response to insulin [6,7]. Phlebotomy or dietary iron 
restriction, in a rat model of T2DM, resulted in decreased glycated hemoglobin levels [8]. Iron 
chelation significantly protected ob/ob mice from diabetes [9] and improved insulin signaling in 
the rat liver [10]. On the other hand, mice fed a high-iron diet have been shown to develop 
insulin resistance [11].  
Increased hepatic glucose production (HGP), driven primarily by increased gluconeogenesis, is a 
characteristic feature of diabetes [12]. Regulation of HGP is a complex process, with glucagon 
and insulin being the primary hormonal regulators [13]. Glucagon stimulates HGP by activating 
(via phosphorylation) the bi-functional enzyme, phosphofructokinase-2/fructose bisphophatase-
2, thus increasing the gluconeogenic flux [14,15]. It also increases the transcription of key 
gluconeogenic genes, phosphoenolpyruvate carboxykinase (PEPCK, Pck1) and glucose-6-
phosphatase (G6pc), by activating the transcription factor, cAMP-response element binding 
protein (CREB) [16]. While glucagon sets the basal tone for HGP, insulin can powerfully 
suppress it by acting through multiple mechanisms [17]. Insulin, acting via its receptor on the 
cell surface, phosphorylates and activates Akt (protein kinase B) [18]. Activated Akt 
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phosphorylates several downstream targets, including glycogen synthase kinase 3β (Gsk3β) (at 
Ser9) and forkhead box O1 (FoxO1) (at Ser256), causing inactivation of both. Inactivation of 
Gsk3β inhibits glycogenolysis, while that of FoxO1 results in suppression of gluconeogenesis 
[19]. In addition to transcriptional regulation of hepatic gluconeogenic genes, it is now known 
that insulin can robustly suppress HGP in mice by acting indirectly, through inhibition of 
lipolysis in the adipose tissue [20]. 
AMP-activated protein kinase (AMPK) is a key cellular energy sensor that is activated in 
response to a multitude of stimuli [21]. AMPK activation results in inhibition of anabolic 
pathways (which consume ATP) and stimulation of catabolic pathways (which increase ATP 
production). AMPK is known to decrease HGP by inducing the phosphorylation and inactivation 
of CREB-regulated transcription co-activator 2 (CRTC2), a key transcriptional co-activator 
involved in induction of gluconeogenic genes by glucagon [22]. In addition, AMPK also inhibits 
glucagon-induced increase in gluconeogenesis, by activating phosphodiesterase-mediated cAMP 
degradation [23].  
Hereditary hemochromatosis comprises a group of conditions characterized by increased body 
iron stores, which results from inappropriately low levels of hepcidin, the central iron regulatory 
hormone [24]. Although raised iron stores are associated with IR (as described above), other 
studies have shown that insulin sensitivity was increased in patients with classical 
hemochromatosis and in mouse models of the condition (Hfe
-/-
 mice) [25,26]. The reason(s) for 
these apparently contradictory findings are not clear; they may be related to the fact that, in 
hemochromatosis, iron accumulates to a greater extent in the liver [27] compared to other tissues, 
such as skeletal muscle and adipose tissue [28]. Such differences in iron levels in tissues may 
potentially affect results from studies done in humans and animal models of hemochromatosis, as 
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glucose tolerance in vivo is determined by factors that regulate insulin sensitivity in both the liver 
and peripheral tissues. For example, insulin has been shown to suppress HGP indirectly by 
inhibiting lipolysis in adipose tissue and not only by acting directly on the liver [20]. In this 
context, the effect of increased levels of iron per se on hepatic insulin signaling and HGP is 
unclear. Similarly, it has been shown that, in mice fed a high-iron diet, AMPK is activated in the 
liver and skeletal muscle; this was associated with decreased HGP [29]. However, it is not 
known whether the decrease in HGP in this context was a direct effect of increased levels of 
hepatic iron or mediated by the effects of iron overload in non-hepatic tissues. 
In the present study, the effects of high intracellular iron levels on insulin signaling and HGP in 
mouse primary hepatocytes were determined. These effects were studied in vitro in order to 
avoid confounding factors that are operational in vivo that would influence the effects that we 
were interested in studying.  
2. Methods 
2.1. Animals 
Male C57Bl/6 mice, aged between 10 and 12 weeks, were used for all the experiments. These 
were carried out with the approval of the Institutional Animal Ethics Committee at Christian 
Medical College, Vellore, India (IAEC No. 8/2014), in accordance with the regulations of the 
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), 
Government of India.   
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2.2. Isolation of mouse primary hepatocytes 
Mouse primary hepatocytes were isolated using a modified collagenase perfusion method, as 
described earlier [30] (see Supplementary Methods for details). Viability of the isolated cells (as 
determined by trypan blue exclusion) was consistently found to be more than 85%. The cells 
were seeded in 6- or 12-well collagen-coated plates at a density of 5 x 10
4
 cells per cm
2
, in 
DMEM with 10% fetal calf serum, and allowed to adhere to the bottom of the wells for 2 hours.  
2.3. Treatment of hepatocytes with iron and/or insulin 
Two hours after seeding, cells were washed with PBS and maintained in serum-free DMEM, 
which was supplemented with ferric ammonium citrate (FAC) at 0, 7.5, 75 or 750 µM 
concentrations for 16 hours (in order to increase the intracellular iron content) [31]. Primary 
hepatocytes were maintained in serum-free DMEM because it is known that serum has an 
inhibitory effect on expression of liver-specific proteins in isolated hepatocytes [32,33]. To study 
the effects of insulin on control or FAC-treated hepatocytes, cells were washed with PBS and 
then treated with insulin (10 nM) for 5 minutes (for study of intracellular signaling events) or 3 
hours (for gene expression studies). A concentration of 10 nM of insulin was chosen because this 
is a concentration that has been commonly used in studies that have assessed insulin signaling in 
primary hepatocytes [34–36]. In addition, our preliminary experiments showed that insulin-
induced activation of Akt (phosphorylation at Ser473) was similar at 10 and 100 nM 
concentrations (data not shown). In a sub-set of hepatocytes treated with FAC (75 μM) for 16 
hours, the cells were washed at the end of the incubation and then incubated with 
desferrioxamine (DFO) (250 μM) for 6 hours, in order to chelate iron. 
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2.4. Determination of cell viability 
At the end of the incubations with FAC, the viability of the cells was determined by the MTT 
assay, estimation of lactate dehydrogenase (LDH) activity in the medium and by staining with 
ethidium homodimer-1 (EthD-1) (see Supplementary Methods for details). 
2.5. Calcein fluorescence quenching by intracellular labile iron  
Intracellular labile iron quenches calcein fluorescence [37] and a decrease in green fluorescence 
indicates increased intracellular labile iron. After treatment with or without FAC, cells were 
washed twice with PBS and incubated with calcein-AM (2 μM final concentration) for 30 min. 
Fluorescence was visualized under a fluorescence microscope using the standard fluorescein 
filter (see Supplementary Methods for details).  
2.6. Hepatocyte glucose production assay 
Hepatocyte glucose production assays were carried out as described earlier [30] (see 
Supplementary Methods for details). Briefly, hepatocytes treated with or without FAC were 
washed and incubated in glucose production buffer (glucose-free, phenol red-free DMEM 
supplemented with lactate [20 mM] or glycerol [10 mM] as the gluconeogenic substrate) for 3, 6, 
9 or 12 hours. At the end of each time point, an aliquot of the medium was taken for estimation 
of glucose by the glucose oxidase-peroxidase (GOD-POD) method. 
2.7. Quantitative real-time PCR (qPCR) 
Quantitative real-time RT-PCR was used to determine the mRNA expression of genes of interest 
(see Supplementary Methods for details). Lysates were prepared from FAC- treated cells or 
control cells and total RNA was isolated using Tri-reagent (Sigma) following standard protocols. 
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The quality of the RNA isolated was ascertained and found to be consistently high. Sequences of 
all primers used are listed in Supplementary Table 1. Expression levels of genes of interest were 
normalized to that of Rpl19 which was used as the reference gene. MIQE check-list and qPCR 
primer validation data are provided in Supplementary Tables 3 and 4 respectively. 
2.8. Western blotting 
FAC-treated and control primary hepatocytes were homogenized in RIPA buffer and processed 
for western blotting, as described earlier [38] (see Supplementary Methods for details). Sources 
and dilutions of primary and secondary antibodies used are listed in Supplementary Table 2.  
2.9. Iron estimation 
Iron content in the FAC-treated and control hepatocytes was measured by a spectrophotometric 
assay, as described previously [39] (see Supplementary Methods for details).  
2.10 Glucose-6-phosphatase enzyme assay 
Enzyme activity of glucose-6-phosphatase (G6Pase) was estimated as described earlier [40] (see 
Supplementary Methods for details). Briefly, microsomal fractions were isolated from primary 
hepatocytes grown in 6-well plates, by differential centrifugation. G6Pase activity was estimated 
by incubating microsomal isolates with the substrate, glucose-6-phosphate (at a final 
concentration of 20 mM), at 30°C for 15 min (pH 6.5). The phosphate released was estimated by 
the method of Taussky and Shorr [41]. One unit of enzyme activity was defined as the amount of 
enzyme that releases 1 μmole of phosphate in one minute. Non-specific hydrolysis of glucose-6-
phosphate, by phosphatases other than G6Pase, was determined by estimation of phosphate 
released when beta-glycerophosphate was used as the substrate (beta-glycerophosphate is not a 
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substrate for G6Pase [42]). Results were corrected for non-specific phosphatase activity and 
normalized to microsomal protein content in each sample. 
2.11. Statistical analyses 
Statistical Package for Social Scientists (SPSS), version 16.0, was used for all statistical 
analyses. The Kruskal-Wallis test was used to look for effects of the various treatments on the 
parameters of interest. Pair-wise comparisons were done using the Mann-Whitney test. 
Correlation analysis was done by Spearman’s correlation test. A p value of less than 0.05 was 
used to indicate statistical significance in all cases. Data was obtained from at least three 
independent experiments (primary hepatocytes isolated from at least 3 different mice), with each 
incubation done in duplicates or triplicates, under the specified conditions.   
3. Results 
3.1. Treatment of hepatocytes with FAC increased intracellular iron content 
Primary hepatocytes treated with FAC, showed increases in cellular iron content (Fig. 1A). This 
was associated with increased protein levels of ferritin (Fig. 1B) and decreased levels of 
transferrin receptor 1 (TfR1) (Fig. 1 C). Intracellular labile iron quenches calcein fluorescence 
and the degree of quenching is indicative of the intracellular labile iron pool (LIP) [37]. By 
fluorescence microscopic imaging, a decrease in calcein fluorescence was found in hepatocytes 
treated with FAC, indicating an increase in the LIP (Fig. 1D). These results show that FAC 
treatment resulted in an increase in intracellular iron with a concomitant increase in the LIP.  
Treatment of hepatocytes with iron did not affect cell viability, as determined by the MTT assay 
(Fig. 1E). However, there was a small but significant increase in LDH activity in the medium, at 
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the highest dose of FAC used (750 μM) (Fig. 1F). Similarly, fluorescence microscopic imaging 
of cells stained with ethidium homodimer-1 (EthD-1), showed a marginal increase in red 
fluorescence in cells treated with 750 μM FAC (Suppl. Fig. 1). There was, however, no change 
in cells treated with 7.5 and 75 μM FAC compared to untreated cells. Treatment of hepatocytes 
with iron induced hepcidin (Hamp1) expression (Suppl Fig 2A). Iron did not affect the mRNA 
expression of the acute-phase proteins, C-reactive protein (Crp) (Suppl Fig 2B) and serum 
amyloid A1 protein (Saa1) (Suppl Fig 2C), and the pro-inflammatory cytokine, interleukin- 6 
(Il6) (Suppl Fig 2D). However, iron induced the expression of tumor necrosis factor alpha (Tnfa) 
(at both 7.5 and 75 µM) (Suppl Fig 2E). Iron also induced the expression of heme oxygenase–1 
(Hmox1) (Suppl Fig 2F) and a small, but statistically significant, increase in the expression of 
Cyba (p22-phox subunit of NADPH oxidase) (Suppl Fig 2G), suggesting the presence of 
oxidative stress in this setting. 
3.2. Treatment with iron increased phosphorylation of Akt and its downstream targets, Gsk3β 
and FoxO1 
Activation of Akt involves phosphorylation at Thr308 and Ser473 [18]. FAC treatment resulted 
in increases in phosphorylation of Akt at both Thr308 and Ser473, without affecting total Akt 
levels (Fig. 2A and B). Increased phosphorylation of downstream targets of activated Akt, viz. 
Gsk3β (Fig. 2C) and FoxO1 (Fig. 2D), was also seen.  Treatment of hepatocytes with DFO (250 
µM) (an iron chelator) for 6 hours after pre-treatment with FAC (for 16 hours) resulted in 
significant decreases in intracellular iron content (Fig. 2E) and was associated with attenuation of 
iron-induced Akt phosphorylation (Fig. 2F). 
3.3. Treatment with iron activated AMP-activated kinase (AMPK) 
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Since AMPK activation has been shown to trigger the phosphorylation and activation of Akt and 
GSK3β in the liver [43], the effect of iron on AMPK was examined in the current study. 
Treatment with FAC induced an increase in the phosphorylation of AMPK at Thr172 (Fig. 3A). 
The downstream target of AMPK, acetyl CoA carboxylase (ACC), was also found to be 
phosphorylated at Ser79 (Fig. 3A; lower panel). Activated AMPK is known to phosphorylate and 
inhibit sterol response element-binding protein 1c (SREBP-1c), resulting in suppression of 
lipogenesis, by decreasing mRNA levels of ACC (Acaca) and fatty acid synthase (Fasn) [44,45]. 
In addition, SREBP-1c inhibition has been shown to result in induction of Irs2 but not of Irs 1 
[46]. In keeping with these reported effects, treatment with FAC was found to reduce mRNA 
expression of Acaca and Fasn, and increase the expression of Irs2 (Fig. 3B, C and D); no 
significant changes were seen in Irs1 expression (Fig. 3E). 
3.4. Treatment with iron decreased hepatocyte glucose production (HGP) 
In order to assess the functional consequences of activation of the Akt and AMPK pathways by 
iron, we measured hepatocyte glucose production (HGP), both in the presence and absence of 
FAC, using lactate and glycerol as gluconeogenic substrates. We used FAC at concentrations of 
7.5 μM and 75 μM for these measurements, avoiding the concentration of 750 μM at which some 
extent of cell damage was observed (Fig 1F and Suppl Fig 1). Hepatocytes treated with FAC at 
75 μM showed significantly lower HGP, when compared to control cells or those treated with 
FAC 7.5 μM; the effects seen were similar irrespective of the use of lactate or glycerol as the 
gluconeogenic substrate (Fig 4A and C). At 7.5 μM, FAC tended to lower glucose production, 
when compared to control cells, but the effects were not statistically significant except at 3 and 6 
h (in the case of lactate-driven basal HGP) (Fig. 4A). Forskolin, an adenylyl cyclase activator 
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that mimics the effects glucagon in hepatocytes [47], was used to induce HGP. Forskolin-
induced HGP was significantly attenuated by FAC (75 μM) treatment (Fig 4B and D). These 
results show that iron significantly decreased both basal and forskolin-induced HGP in 
hepatocytes. Treatment with insulin, on the other hand, did not have an effect on HGP, neither in 
the presence of forskolin nor in its absence (Suppl Fig 3) 
Since similar changes in HGP were found irrespective of lactate or glycerol being used as the 
gluconeogenic substrate, effects of iron on gene expression and activity of glucose-6-
phosphatase (G6Pase) (an enzyme involved in gluconeogenesis from both of these substrates) 
was determined. Treatment of hepatocytes with FAC at 7.5 μM did not produce any significant 
effect on G6Pase mRNA levels; treatment with 75 μM of FAC a small but significant increase in 
levels (Fig. 4E). However, activity of G6Pase was lower in hepatocytes treated with FAC, with a 
concentration-dependent effect seen, but the decreases were not statistically significant (Fig. 4F). 
Prior treatment of hepatocytes with FAC attenuated forskolin-induced increases in G6Pase 
mRNA (Fig. 4E) and activity (Fig. 4F), with the attenuation being more marked with increasing 
concentrations of iron. Iron also attenuated insulin-induced suppression of G6Pase mRNA (Fig. 
5C). A similar pattern was observed in G6Pase activity as well (though the effects were not 
statistically significant) (Fig. 5D).  
3.5. Treatment with iron rendered hepatocytes less sensitive to insulin-induced activation of the 
Akt pathway 
In order to assess the effect of iron on insulin-induced activation of the Akt pathway, hepatocytes 
were incubated with different doses of FAC for 16 h followed by treatment for 5 min with 
insulin (10 nM). Insulin-induced activation of Akt (Fig. 5A), as well as Gsk3β (Fig 5B) (the 
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downstream target of activated Akt), was significantly attenuated by treatment with iron. In 
keeping with this observation, insulin was found to neither suppress G6pc (Fig. 5C) nor induce 
glucokinase (Gck) (Fig. 5E) in FAC-treated hepatocytes. Both of these are known responses to 
insulin and were observed in the current study in the absence of FAC treatment (Fig. 5C and E). 
These results suggest that increased intracellular iron rendered hepatocytes resistant to the effects 
of insulin.  
3.6. Iron down-regulated protein levels of IRS1 and IRS2 
Insulin receptor substrates 1 and 2 (IRS 1 and 2) are upstream of Akt in the insulin signaling 
pathway. With increasing concentration of FAC, protein levels of IRS1 and IRS2 decreased (Fig. 
6A and B). Phosphorylation of IRS1 at Ser307 (Fig. 6C) and Ser789 (Fig. 6D), both of which are 
known to inhibit signaling via IRS-1, tended to increase progressively in response to increasing 
concentrations of FAC, but the increases were statistically significant only at 750 µM FAC. 
There was also no demonstrable activation of JNK (c-Jun N-terminal kinase), a stress-induced 
kinase known to phosphorylate IRS1 at Ser307 (Fig. 6F).  
3.7 Correlational analyses 
Results of correlation analyses showed that, in FAC-treated hepatocytes, intracellular iron levels 
were significantly and positively correlated with p-Akt (Ser473), p-Akt (Thr308), p-Gsk3β 
(Ser9), p-FoxO1 (Ser256) and p-AMPK (Thr172), and negatively correlated with IRS1 and IRS2 
protein levels. In addition, markers of insulin signaling (p-Akt [Ser473], p-Akt [Thr308], p-Gsk 
[Ser9] and p-FoxO1 [Ser256]) were significantly and positively correlated with one another and 
with p-AMPK (Thr172) (Table 1). 
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4. Discussion 
Molecular interactions between insulin signaling and iron in hepatocytes, and their effects on 
HGP have not been clearly elucidated. In order to study this, we used mouse primary 
hepatocytes, which were iron-loaded in vitro by incubation with FAC at various concentrations. 
In vitro systems do have limitations; however, in this context, this was the most appropriate 
model to use to answer the research question concerned, since we wished to avoid confounding 
factors that are operational in vivo (as described in the introduction section). The rationale for 
treating hepatocytes with FAC (a highly soluble form of iron) was to increase intracellular iron 
content. The doses of FAC chosen were based on a previous publication where primary 
hepatocytes treated with similar doses of FAC showed no decrease in cell viability [31].  In 
addition, FAC was chosen because ferric citrate is a physiologically relevant form of iron. It has 
been shown that non-transferrin bound iron (NTBI), which increases in blood in conditions of 
iron overload, such as hemochromatosis and thalassemia, is mainly found complexed with citrate 
[48,49].  
Treatment of hepatocytes with FAC resulted in increases in intracellular iron content (Fig. 1 A-
C). Although MTT assay showed no significant decrease in cell viability (Fig. 1D), there was a 
small but significant increase in LDH activity in the medium (Fig. 1 E) and increased EthD-
1fluorescence (Suppl. Fig. 1) at the highest dose of FAC used (750 µM). This showed that FAC, 
at this dose, induced cell damage to a certain extent. However, all the effects of interest produced 
by treatment with FAC, which are reported in this study, were seen at 7.5 and 75 µM 
concentrations.  No decrease in cell viability was seen at these doses.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
The results of our study are summarized in Fig 7. Overall, the results showed that increases in 
intracellular iron had a dual effect on hepatocytes, with regard to the pathway of insulin 
signaling. On one hand, iron activated the Akt signaling pathway in hepatocytes in a ligand-
independent manner, i.e., even in the absence of insulin (Fig. 2). In addition, iron activated 
AMPK, a key energy-sensing pathway (Fig. 3). Consequently, gluconeogenesis was down-
regulated and HGP was decreased (Fig. 4). On the other hand, iron attenuated activation of the 
Akt pathway in response to insulin (Fig. 5); this was associated with decreased levels of IRS 1 
and 2 (Fig. 6), thereby resulting in a state of insulin resistance. The findings of this study provide 
a plausible explanation for why iron overload, in general, is associated with insulin resistance (1–
11) but improved glucose tolerance and insulin sensitivity is seen in classical hemochromatosis 
(which is characterized by iron overload primarily in the liver) [25,26].  To the best of our 
knowledge, our findings, in primary hepatocytes, are novel and have not been reported earlier. 
AMPK is activated by its upstream kinase, liver kinase B1 (LKB1), by phosphorylation at 
Thr172 [21]. It has been shown previously that LKB1 and AMPK were activated in the liver and 
skeletal muscle of mice fed a high-iron diet [29]. Ligand-independent activation of the Akt 
pathway has been shown to occur in response to activation of AMPK [50,51], thus suggesting a 
likely mechanism by which Akt phosphorylation is induced by iron. FAC treatment resulted in 
activation of AMPK, which was highly significantly correlated with phosphorylation of Akt at 
both Thr308 and Ser473 (Table 1). It is, therefore, possible that iron-induced activation of Akt 
may be mediated by AMPK activation. Additional studies, utilizing techniques of gene knock-
down and pharmacological inhibition of AMPK, would be required to confirm this. 
It has been shown that di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), a novel 
iron and copper chelator that has been shown to have anti-cancer activity, increases AMPK 
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activity in various cancer cell lines [52]. This is in contrast to the results of the present study 
where we have shown activation of AMPK in response to an increase in intracellular iron (Fig 
3A). The exact mechanisms that underlie metal-ion chelation-induced activation of AMPK have 
not been clearly elucidated; however, there are several possible mechanisms. Both iron and 
copper are critical for mitochondrial electron transport chain [53]. Chelation of iron and copper 
by Dp44mT can therefore inhibit oxidative phosphorylation resulting in accumulation of AMP, 
which is a potent activator of AMPK [21]. Dp44mT is also known to generate ROS and induce 
oxidative stress in cells [52]; oxidative stress is known to activate AMPK [21].  
Iron decreased basal as well as forskolin-induced HGP (Fig. 4A to D). It also attenuated 
forskolin-induced increases in mRNA expression of G6pc (Fig. 4E).  Activation of the Akt 
pathway results in suppression of gluconeogenesis by inhibiting FoxO1-induced expression of 
G6pc [54,55]. Activation of AMPK has also been shown to decrease HGP by inducing the 
phosphorylation and inactivation of CRTC2, a key transcriptional co-activator involved in 
induction of gluconeogenic genes by glucagon [22]. In addition, AMPK inhibits glucagon-
induced increase in G6pc expression by activating phosphodiesterase-mediated cAMP 
degradation [23]. Therefore, iron-induced activation of Akt and AMPK pathways can explain the 
decrease in HGP and G6pc expression in this setting. 
The rate of glucose uptake by hepatocytes is chiefly regulated by glucokinase (GK) [56]. Insulin 
increases hepatocyte glucose uptake by increasing transcription of the gene for glucokinase 
(Gck) [57]. Consistent with this, our data shows that insulin induced mRNA expression of Gck; 
however, in the presence of iron, this effect was attenuated, while treatment of the cells with only 
iron did not affect Gck mRNA levels (Fig 5E). This tends to suggest that glucose uptake may not 
be affected in hepatocytes treated with iron. We attempted to estimate glucose uptake in 
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hepatocytes in this setting using a 2-deoxyglucose (2-DG) uptake assay (Cosmo Bio, Japan). 
However, we were unable to obtain reliable estimates of 2-DG uptake in hepatocytes due to high 
background signal obtained in the negative controls (hepatocytes not treated with 2-DG). This is 
a limitation of the present study. 
Decreased HGP was seen in response to iron but was not associated with a corresponding 
decrease in expression of G6pc. In fact, iron (at 75 µM, but not at 7.5 µM) induced a small but 
significant increase in the mRNA levels of this enzyme (Fig. 4E). The reasons for decreased 
HGP in response to iron treatment are currently unclear. HGP is known to be regulated by post-
translational mechanisms through the control of substrate flux, rather than exclusively by 
changes in gene expression [13]. We, therefore, estimated G6Pase enzyme activity in 
hepatocytes treated with iron. Activity of this enzyme was not affected by FAC treatment (Fig 
4F). This seems to suggest that the inhibitory effect of iron on HGP is possibly not mediated by 
post-translational effects of iron on G6Pase enzyme activity. 
The bi-functional enzyme, phosphofructokinase-2 /fructose–2,6–bisphosphatase (PFKFB), is a 
key enzyme involved in the reciprocal regulation of glycolysis and gluconeogenesis [58]. Insulin, 
by acting via the Akt pathway, can activate PFKFB (by de-phosphorylation), thus stimulating 
glycolysis and inhibiting gluconeogenesis. On the other hand, glucagon, acting via the second 
messenger cAMP, inactivates PFKFB (by phosphorylation)  and has the opposite effect [59]. It is 
possible that iron-induced activation of the Akt pathway may underlie the decrease in HGP seen 
in this setting. In addition, activation of AMPK is known to decrease HGP by antagonizing 
glucagon signaling via phosphodiesterase-mediated degradation of cAMP [23].  Further work 
would be required to investigate these possibilities. A possible explanation for the increase in 
G6pc expression induced by FAC treatment (at 75 μM) (Fig 4E) may be iron-induced 
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mitochondrial dysfunction, which has been shown to occur in response to iron overload and 
result in increased expression of gluconeogenic genes [60].  
Although treatment with iron activated the Akt pathway, activation of Akt (and its downstream 
target, GSK3β) in response to insulin treatment was significantly attenuated in iron-loaded 
hepatocytes (Fig 5A and B), suggesting that an iron-overloaded state results in resistance to the 
actions of insulin. We attempted to elucidate the functional consequences of this observation by 
studying HGP changes in response to insulin treatment. However, we found that insulin did not 
have an effect on HGP, neither in the presence of forskolin nor in its absence (Suppl Fig 3). This 
is consistent with recent studies which have shown that direct insulin signaling in hepatocytes is 
dispensable for insulin-mediated down-regulation of HGP [20,61]. Regulation of HGP by insulin 
in vivo has been suggested to be mediated by an intermediate extra-hepatic organ/tissue; this is 
most probably the adipose tissue, via changes in free fatty acid levels in blood [62].   
In the present study, iron induced a progressive decrease in IRS1 and IRS2 protein levels (Fig. 
6A and B). Since IRS1 and IRS2 are up-stream of Akt in the insulin signaling cascade, a 
decrease in the levels of these proteins could account for the impaired phosphorylation and 
decreased activation of Akt induced by insulin in these cells. Phosphorylation of IRS1 at Ser307 
and its subsequent degradation has been proposed to play a key role in the development of 
insulin resistance [63]. Stress-induced protein kinases, including JNK and mTOR, are known to 
increase phosphorylation of IRS1 at Ser307 [64,65].  Our findings show that treatment with iron 
induced an increase in the p-IRS1 (Ser307)/total IRS1 ratio (Fig. 6C), but did not activate JNK 
(Fig. 6E). It is possible that increased phosphorylation of IRS1 at Ser307 in this setting could be 
mediated by mTOR; however, this possibility requires further exploration. In addition, iron 
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increased IRS1 phosphorylation at Ser789 (Fig. 6D). Phosphorylation of IRS-1 at Ser789 is 
known to be induced by AMPK [50] and inhibits signal transduction via IRS1 [66].  
We found that treatment with iron induced the expression of TNF-alpha in isolated hepatocytes 
(Suppl Fig 2E). It has been previously shown that chronic iron loading (by administration of 
iron-dextran) in rats resulted in induction of TNF-alpha,  but not of other cytokines, such as IL-6 
and TGF-alpha, in the liver [67]. On the other hand, human primary hepatocytes, treated with 
holo-transferrin, showed induction of both TNF-alpha as well as IL-6 [68]. Additional studies 
would be required to elucidate the mechanisms that underlie the induction of TNF alpha by iron, 
and its pathophysiological significance, if any.  
Findings of increased basal but decreased insulin-stimulated activation of Akt have been reported 
previously to result in insulin resistance. For example, it has been shown that overexpression of a 
constitutively active form of Akt increased basal glucose uptake, but blunted insulin-induced 
glucose uptake in cardiomyocytes [69]. Similarly, cardiomyocytes that over-expressed FoxO1, 
showed elevated basal, but impaired insulin-stimulated Akt phosphorylation and downstream 
insulin signaling [70]. Hfe
-/-
 mice, that represent a model of hemochromatosis, also show 
increased basal, but not insulin-stimulated glucose uptake in the skeletal muscle [25]. Impaired 
activation of Akt in response to insulin treatment has also been shown in AML-2 mouse 
hepatocyte cell lines which were iron-loaded [71]. These findings support the results of the 
current study. 
In conclusion, the results of this study show that increased levels of intracellular iron, in mouse 
primary hepatocytes in vitro, activated the Akt and AMPK pathways and resulted in decreased 
HGP. Insulin-induced activation of the Akt pathway was attenuated in these cells, possibly due 
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to decreased protein levels of IRS1/2 (Fig. 7). These findings may help explain why both insulin 
resistance and increased sensitivity have been observed in iron-overloaded states. They are of 
relevance to disease conditions characterized by hepatic iron overload such as hemochromatosis, 
thalassemia and non-alcoholic steatohepatitis, which are disorders known to be associated with 
increased risk of type 2 diabetes. 
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Figure legends 
Fig. 1: Treatment of hepatocytes with FAC increased intracellular iron content 
A: Intracellular iron levels estimated using a bathophenanthrolene-based colorimetric assay.  
B and C: Representative images and densitometric quantification of western blots for ferritin 
(light chain) (B) and TfR1 (C). Bands obtained for β-actin are shown as loading controls. 
D: Representative fluorescent microscopic images showing quenching of calcein fluorescence by 
treatment with FAC. Images shown in 10x magnification. 
E and F: Determination of cell viability by MTT assays (E) and estimation of LDH activity in the 
medium (F) following treatment of cells with FAC. 
Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate or triplicate, under the specified conditions.  Dissimilar alphabets against bars in each 
panel indicate data that are significantly different from one another. A p value <0.05 was taken to 
indicate statistical significance in all cases.  
Figure 2: Treatment with iron increased phosphorylation of Akt and its downstream 
targets, Gsk3β and FoxO1 
A-D: Mouse primary hepatocytes were treated with FAC at various concentrations (as indicated) 
for 16 hours. Representative images for western blots and densitometric quantification of the 
bands obtained are shown for p-Akt [Thr308]/Akt (A), p-Akt [Ser473]/Akt (B), p-Gsk3β [Ser9]/ 
Gsk3β (C) and p-FoxO1 [Ser256]/FoxO1 (D). Bands obtained for β-actin are shown as loading 
controls. 
E and F: Hepatocytes treated with FAC (75 µM) for 16 hours were washed and further treated 
with DFO (250 µM) for 6 hours. Intracellular iron content (E) estimated at the end of the 
incubation periods and representative images and densitometric quantification of the bands for 
pAkt (Ser473)/Akt (F) are shown. Bands obtained for β-actin are shown as loading controls. 
Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate or triplicate, under the specified conditions. Dissimilar alphabets against bars in each 
panel indicate data that are significantly different from one another. A p value <0.05 was taken to 
indicate statistical significance in all cases. In panel F, * indicates p <0.05. 
Figure 3: Treatment with iron activated AMP-activated kinase (AMPK) 
A: Representative images of western blots for p-AMPK (Thr172)/AMPK and p-ACC 
(Ser79)/ACC and densitometric quantification of bands obtained for p-AMPK (Thr172)/AMPK 
are shown. Bands obtained for β-actin are shown as loading controls. 
B-E: Gene expression (determined by qPCR) of acetyl CoA carboxylase (Acaca) (B), fatty acid 
synthase (Fasn) (C), IRS-2 (Irs2) (D) and IRS-1 (Irs1) (E). 
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Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate or triplicate, under the specified conditions. Dissimilar alphabets against bars in each 
panel indicate data that are significantly different from one another. A p value <0.05 was taken to 
indicate statistical significance in all cases. 
Figure 4: Treatment with iron decreased hepatocyte glucose production (HGP) 
A and B: HGP assay using lactate as the gluconeogenic substrate in the presence (B) or absence 
(A) of forskolin (25μM) for 3 h. 
C and D: HGP assay using glycerol as the gluconeogenic substrate in the presence (D) or 
absence (C) of forskolin (25μM) for 3 h. 
E and F: Gene expression (determined by qPCR) of G6pc (E) and G6Pase enzyme activity (F) in 
the presence and absence of forskolin (25 μM) for 3 h. 
Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate or triplicate, under the specified conditions. In A-D, * indicates p<0.05 compared to 
FAC at 0 μM and # indicates p<0.05 when compared to FAC at 7.5 μM. In E and F, dissimilar 
alphabets against bars in each panel indicate data that are significantly different from one 
another. A p value <0.05 was taken to indicate statistical significance in all cases.  
Figure 5: Treatment with iron rendered hepatocytes less sensitive to insulin-induced 
activation of the Akt pathway 
A and B: Hepatocytes were treated with FAC at various concentrations (as indicated) for 16 
hours and then treated with insulin (10 nM) or normal saline for 5 min. The effect of insulin 
treatment on phosphorylation of Akt (A) or Gsk3β (B) was determined as a ratio of p-Akt or p-
GSK3β levels in the presence of insulin to that in its absence. Bands obtained for β-actin are 
shown as loading controls. 
C, D and E: Hepatocytes were treated with FAC at various concentrations (as indicated) for 16 
hours and then treated with insulin (10 nM) or normal saline for 3 hours. Gene expression of 
G6pc (C) and Gck (E) (determined by qPCR) and G6Pase enzyme activity (D) are shown. 
Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate or triplicate, under the specified conditions. Dissimilar alphabets against bars in each 
panel indicate data that are significantly different from one another. A p value of less than 0.05 
was taken to indicate statistical significance in all cases.  
Figure 6: Iron down-regulated protein levels of IRS1 and IRS2  
Representative images and densitometric quantification of western blots for IRS1 (A), IRS2 (B), 
p-IRS1 (Ser307)/total IRS1 (C), p-IRS1 (Ser789)/total IRS1 (D) and p-JNK (E) are shown. 
Bands obtained for β-actin are shown as loading controls. 
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Data represent mean ± SD of results obtained from at least three independent experiments 
(primary hepatocytes isolated from at least 3 different mice), with each incubation done in 
duplicate, under the specified conditions. Dissimilar alphabets against bars in each panel  
indicate data that are significantly different from one another. A p value of less than 0.05 was 
taken to indicate statistical significance in all cases.  
Figure 7: Schematic diagram of the proposed effect of intracellular iron on insulin 
signaling 
Increased intracellular iron activated the Akt and AMPK pathways, resulting in decreased 
gluconeogenesis and hepatocyte glucose production. In addition, iron decreased levels of IRS-1 
and 2, which are upstream of Akt in the insulin signaling pathway, resulting in decreased insulin-
stimulated activation of the Akt pathway.  
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Table 1: Correlation analyses among parameters of interest in primary hepatocytes treated with iron 
Sl. 
no 
Parameter Parameter Spearman’s 
correlation 
coefficient 
p-value 
1 Intracellular iron level vs. p-Akt (Ser473) 0.648 0.004 
p-Akt (Thr308) 0.843 <0.001 
p-Gsk3β (Ser9) 0.771 0.003 
p-FoxO1 (Ser256) 0.652 0.008 
p-AMPK (Thr172) 0.812 <0.001 
p-IRS1 (Ser307) 0.470 0.049 
Total IRS1 - 0.667 0.002 
Total IRS2 - 0.684 0.007 
2 p-Akt (Ser473) vs. p-Akt (Thr308) 0.671 0.004 
p-Gsk3β (Ser9) 0.638 0.025 
p-FoxO1 (Ser256) 0.574 0.020 
p-AMPK (Thr172) 0.649 0.001 
3 p-Akt (Thr308) vs. p-Gsk3β (Ser9) 0.997 <0.001 
p-FoxO1 (Ser256) 0.641 0.007 
p-AMPK (Thr172) 0.747 0.001 
4 p-Gsk3β (Ser9) vs. p-FoxO1 (Ser256) 0.713 0.009 
p-AMPK (Thr172) 0.716 0.009 
5 p-FoxO1 (Ser256) vs. p-AMPK (Thr172) 0.515 0.041 
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Highlights 
 Increased cellular iron levels activated Akt and AMPK signaling in hepatocytes.   
 These effects were associated with decreased hepatic glucose production (HGP).  
 Iron decreased insulin-induced activation of Akt and forskolin-induced HGP.  
 Increased intracellular iron levels altered insulin sensitivity in hepatocytes.  
 It caused basal activation of Akt and attenuation of insulin-induced activation.  
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